Entries by Michelle Smith

, ,

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

Author: Alex Capano, Richard Weaver & Elisa Burkman Published in Postgraduate Medicine   November 2019 Abstract Context: Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy…

, ,

A Comprehensive Patient and Public Involvement Program Evaluating Perception of Cannabis-Derived Medicinal Products in the Treatment of Acute Postoperative Pain, Nausea, and Vomiting Using a Qualitative Thematic Framework

Author: Simon Erridge, Marie Miller, Tamara Gall, Antonio Costanzo, Barbara Pacchetti, and Mikael H. Sodergren Published in Mary Ann Liebert, Inc Publishers  February 2020 Abstract Introduction: Cannabis-derived medicinal products (CDMPs) have antiemetic properties and in combination with opioids have synergistic analgesic effects in part signaling through the delta and kappa opioid receptors. The objective of this patient…

Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

Authors: Belén Palomares, Martín Garrido‐Rodriguez, Claudia Gonzalo‐Consuegra, María Gómez‐Cañas, Suwipa Saen‐oon, Robert Soliva, Juan A. Collado, Javier Fernández‐Ruiz, Gaetano Morello, Marco A. Calzado, Giovanni Appendino, Eduardo Muñoz Published in British Journal of Pharmacology  June 2020 Abstract Background and Purpose: Δ9‐Tetrahydrocannabinolic acid (Δ9‐THCA‐A), the precursor of Δ9‐THC, is a non‐psychotropic phytocannabinoid that shows PPARγ agonist activity. Here,…

The practical knowledge, experience and beliefs of US emergency medicine physicians regarding medical Cannabis: A national survey

Author: Kevin M Takakuwa, Frances S Shofer, Raquel M Schears Published in The American Journal of Emergency Medicine  January 2020 Abstract Medical cannabis is legal in 33 US states [ 1 ] but remains federally illegal. The majority of legal states require physicians to provide cannabis recommendations in order for patients to have access to it….

,

Assessment of the Association of Cannabis on Female Sexual Function With the Female Sexual Function Index

Author: Alex M. Kasman, MD, MS, Hriday P. Bhambhvani, BS, Genester Wilson-King, MD, and Michael L. Eisenberg, MD Published in Science Direct  July 2020 Abstract Introduction: Cannabis use has increased in the last decade, and the impact of cannabis on female sexual function remains unclear. Aim: To assess the impact of frequency of use, chemovar (tetrahydrocannabinol,…

, ,

Alleviative effects of Cannabis flower on migraine and headache

Author: Sarah S. Stitha, Jegason P.Diviant, Franco Brockelman, KeenanKeeling, BrandenHall, Storri Lucern, Jacob M.Vigil, Kathleen MacMillan MacMillan, Amanda Keddy, James Furlon Published in Science Direct July 2020 Abstract Objective: Few studies to date have measured the real-time effects of consumption of common and commercially available Cannabis products for the treatment of headache and migraine under naturalistic…

, ,

A Comprehensive Patient and Public Involvement Program Evaluating Perception of Cannabis-Derived Medicinal Products in the Treatment of Acute Postoperative Pain, Nausea, and Vomiting Using a Qualitative Thematic Framework

Author: Simon Erridge, Marie Miller, Tamara Gall, Antonio Costanzo, Barbara Pacchetti, and Mikael H. Sodergren Published in Mary Ann Liebert, Inc Publishers  February 2020 Abstract Introduction: Cannabis-derived medicinal products (CDMPs) have antiemetic properties and in combination with opioids have synergistic analgesic effects in part signaling through the delta and kappa opioid receptors. The objective of this…

,

The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies

Author: Anna Porcella Chiara Maxia Gian Luigi Gessa Luca Pani Published in European Journal of Neuroscience March 1980 Abstract The search for new ocular hypotensive agents represents a frontier of current eye research because blindness due to optic neuropathy occurs insidiously in 10% of all patients affected by glaucoma. Cannabinoids have been proposed to lower intraocular…

,

Topical Δ9‐Tetrahydrocannabinol and Aqueous Dynamics in Glaucoma

Author: JOHN C. MERRITT M.D. DWIGHT D. PERRY M.D. DAVID N. RUSSELL M.D. BRENDA F. JONES M.D. Published in American College of Clinical Pharmacology  September 1981 Abstract Systemic Δ9‐tetrahydrocannabinol (THC), administered either by smoking marihuana or as synthetic THC in soft gelatin capsules, lowers ocular tension in various glaucomas, but at the expense of significant decreases…

,

Effect of Marihuana on Intraocular and Blood Pressure in Glaucoma

Author: John C.Merritt MD, William J.Crawford PhD, Paul C.Alexander MD, Alfred L.Anduze MD, Solomon S.Gelbart MD Published in Science Direct March 1980 Abstract Marihuana inhalation was accompanied by increased heart rate and decreased intraocular and blood pressure in 18 subjects with heterogenous glaucomas. The hypotensive effects appeared in 60 to 90 minutes as the decrease in…

,

Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration

Author: I. Matias, J.W. Wang, A. Schiano Moriello, A. Nieves, D.F. Woodward,V. Di Marzo Published in Science Direct December 2006 Abstract Cannabinoid receptors and the endocannabinoids (anandamide (N-arachidonoylethanolamine—AEA) and 2-arachidonoylglycerol (2-AG)), as well as the AEA congener, palmitoylethanolamide (PEA), are involved in ocular physiology. We measured endocannabinoid and PEA levels by isotope-dilution liquid chromatography-mass spectrometric analysis…

,

Cannabis and glaucoma: A literature review

Author: Kathleen MacMillan MacMillan, Amanda Keddy, James Furlon Published in Dalhousie Medical Journal  2019 Abstract Introduction: Primary open-angle glaucoma (POAG) is characterized by the loss of retinal ganglion cells secondary to optic neuropathy; increased intraocular pressure (IOP) may or may not be present. Many treatment options focus on decreasing IOP measurements to attempt to prevent progression…